The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Faizuloev E.B.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Kaira A.N.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Uzbekov T.R.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Poromov A.A.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Volynskaya E.A.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Svitich O.A.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Zverev V.V.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

The prevalence of high and low risk human papillomaviruses in the Russian Federation

Authors:

Faizuloev E.B., Kaira A.N., Uzbekov T.R., Poromov A.A., Volynskaya E.A., Svitich O.A., Zverev V.V.

More about the authors

Journal: Molecular Genetics, Microbiology and Virology. 2021;39(4): 39‑47

DOI: 10.17116/molgen20213904139

Read: 12654 times

Download PDF (RU)
Contact the author
Table of contents

THE PREVALENCE OF HIGH AND LOW RISK HUMAN PAPILLOMAVIRUSES IN THE RUSSIAN FEDERATION
THE PREVALENCE OF HIGH AND LOW RISK HUMAN PAPILLOMAVIRUSES IN THE RUSSIAN FEDERATION

To cite this article:

Faizuloev EB, Kaira AN, Uzbekov TR, Poromov AA, Volynskaya EA, Svitich OA, Zverev VV. The prevalence of high and low risk human papillomaviruses in the Russian Federation. Molecular Genetics, Microbiology and Virology. 2021;39(4):39‑47. (In Russ.)
https://doi.org/10.17116/molgen20213904139

Подписка 2026 Молекулярная генетика, микробиология и вирусология (Molecular Genetics, Microbiology and Virology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Bioinformatic sele­ction of the most opti­mal restriction endo­nuclease combinations for geno­typing major agri­cultural crops using the GBS method. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4-2):157-162
Prevalence of postpartum depression in the Russian Fede­ration: a systematic review and meta-analysis. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):74-87
Legal regu­lation of the human genome editing technologies application: inte­rnational standards and the national practices. Russian Journal of Preventive Medi­cine. 2025;(10):7-15
Epidemiology of inhe­rited epidermolysis bullosa in the Russian Fede­ration. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(5):574-582
Russian Fede­ration public nutritional awareness. Russian Journal of Preventive Medi­cine. 2026;(1):34-39
Abstract:

THE AIM OF THE STUDY

Was to assess the prevalence of high-risk and low-risk human papillomaviruses (HPV) types in the Russian Federation.

MATERIALS AND METHODS

Clinical samples (urogenital swabs) were obtained during 2019 from patients with suspected HPV urogenital infection of different sex and ages living in different regions of the Russian Federation (n=12 945). HPV genotyping was performed using the real-time PCR kit QUANT-21 («DNA-Technology», Russia), which allows differential detection of high-risk HPV types 31, 35, 52, 33, 68, 45, 82, 51, 39, 58, 66, 26, 53, 59, 56, 73, 16, 18 and low-risk HPV types 6, 11 and 44.

RESULTS

In clinical samples of 5013 patients, 8593 HPV-types were detected (mono infection — in 3057 patients, mixed infection — in 1956 patients). It was shown that on the Russian Federation, the dominant HPV-types are HPV16 — 13.8% (95% CI 13.0—14.5), HPV6 — 10.7% (10.0—11.3), HPV51 — 6.8% (6.3—7.3), HPV44 — 6.8% (6.2—7.3), HPV53 — 6.3% (5.8—6.8), HPV31 — 5.6% (5.2—6.2), HPV56 — 5.5% (5.0—6.0), HPV52 — 5.4% (5.0—5.9), while the percentage of other types varied from 5 to 0.4%. Age, gender, and regional distribution of different HPV types were described.

CONCLUSION

The monitoring of circulating HPV strains will allow predicting the effectiveness of HPV vaccines of various compositions in the Russian Federation, and is of interest in the development of domestic HPV vaccines.

Keywords:

human papillomaviruses
HPV
genotyping
high-risk HPV
low-risk HPV
Russian Federation
human papillomaviruses
HPV
genotyping
high-risk HPV
low-risk HPV
Russian Federation

Authors:

Faizuloev E.B.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Kaira A.N.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Uzbekov T.R.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Poromov A.A.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Volynskaya E.A.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Svitich O.A.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Zverev V.V.

FSBSI «I. Mechnikov Research Institute of Vaccines and Sera»

Received:

26.11.2020

Accepted:

10.01.2021

Close metadata

References:

  1. de Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324(1):17-27.  https://doi.org/10.1016/j.virol.2004.03.033
  2. Bzhalava D, Eklund C, Dillner J. International standardization and classification of human papillomavirus types. Virology. 2015;476,341-344.  https://doi.org/10.1016/j.virol.2014.12.028
  3. Harden ME, Munger K. Human papillomavirus molecular biology. Mutat Res Rev Mutat Res. 2017;772:3-12.  https://doi.org/10.1016/j.mrrev.2016.07.002
  4. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 2011;19(1):33-39.  https://doi.org/10.1016/j.tim.2010.10.002.
  5. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-670.  https://doi.org/10.1002/ijc.30716
  6. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018;47:14-26.  https://doi.org/10.1016/j.bpobgyn.2017.08.006
  7. Chaturvedi AK. Beyond cervical cancer: burden of other HPV-related cancers among men and women. J Adolesc Health. 2010;46(suppl 4):20-26.  https://doi.org/10.1016/j.jadohealth.2010.01.016
  8. Grulich AE, Jin F, Conway EL, Stein AN, Hocking J. Cancers attributable to human papillomavirus infection. Sex Health. 2010;7(3):244-252.  https://doi.org/10.1071/SH10020
  9. Baranov AA, Plakida AV, Namazova-Baranova LS, Semenov MA, Ilyushina OV, Guretskiy YV, et al. Analysis of the Economic and Socio-Demographic Burden of HPV-Associated Diseases and the Cost-Effectiveness of HPV Vaccination in Russia. Pediatric pharmacology. 2019;16(2):101-110. (In Russ.).
  10. Guan P, Howell-Jones R, Li N, Bruni L, de Sanjosé S, Franceschi S, Clifford GM. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer. 2012;131(10):2349-2359. https://doi.org/10.1002/ijc.27485.
  11. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer? J Pathol. 2014;234(4):431-435.  https://doi.org/10.1002/path.4424. PMID: 25124771.
  12. Poljak M, Seme K, Maver PJ, Kocjan BJ, Cuschieri KS, Rogovskaya SI, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe. Vaccine. 2013;31(suppl 7):59-70.  https://doi.org/10.1016/j.vaccine.2013.03.029
  13. Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Vaccine. 2013;31(suppl 7):46-58.  https://doi.org/10.1016/j.vaccine.2013.06.043
  14. Kisseljova N, Zhordania K, Fedorova M, Katargin A, Valeeva A, Pajanidi J et al. Detection of Human Papillomavirus Prevalence in Ovarian Cancer by Different Test Systems. Intervirology. 2019;62(5-6):198-204.  https://doi.org/10.1159/000506050
  15. Smelov V, Elfström KM, Eklund C, Sokolova O, Dillner J. Determinants of the presence of human papillomaviruses in the anal canal of Russian men. J Med Virol. 2018;90(10):1643-1650. https://doi.org/10.1002/jmv.25234.
  16. Roik E, Sharashova E, Kharkova O, Nieboer E, Postoev V, Odland JØ. Sociodemographic characteristics, sexual behaviour and knowledge about cervical cancer prevention as risk factors for high-risk human papillomavirus infection in Arkhangelsk, North-West Russia. Int J Circumpolar Health. 2018;77(1):1498681. https://doi.org/10.1080/22423982.2018.1498681
  17. Kulmala SM, Shabalova IP, Petrovitchev N, Syrjänen KJ, Gyllensten UB, Syrjänen SM. Prevalence of the most common high-risk HPV genotypes among women in three new independent states of the former Soviet Union. J Med Virol. 2007;79(6):771-781.  https://doi.org/10.1002/jmv.20839.
  18. Nazarova NM, Burmenskaya OV, Sulamanidze LA, Prilepskaya VN, Pavlovich SV, Trofimov DYu. Prevalence of anogenital human papillomavirus types in patients with HPV-associated cervical diseases. Akusherstvo i Ginekologiya. 2015;12:89-96. (In Russ.).
  19. Donnikov AE, Markelov MI, Pestrikova TYu, Yurasova EA, Kotelnikova AV, Voroshilina ES, et al. Analysis of the prevalence and viral load of different human papillomavirus types in the regions of the Russian Federation. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2019;(4):39-48. (In Russ.). https://doi.org/10.18565/aig.2019.4.39-47
  20. Cohen DA, Farley TA, Taylor SN, Martin DH, Schuster MA. When and where do youths have sex? The potential role of adult supervision. Pediatrics. 2002;110(6):e66.  https://doi.org/10.1542/peds.110.6.e66.
  21. Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine. 2008;26(suppl 10):1-16.  https://doi.org/10.1016/j.vaccine.2008.05.064
  22. Lopalco PL. Spotlight on the 9-valent HPV vaccine. Drug Des Devel Ther. 2017;11:35-44.  https://doi.org/10.2147/DDDT.S91018
  23. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B et al. Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048-1056. https://doi.org/10.1016/S1470-2045(10)70230-8
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.